Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/10/201005144634.htm
No comments:
Post a Comment